FUNDAMENTALS · Fundamentals · US Healthcare

Contineum Therapeutics (CTNM) Fundamentals 2026 — Revenue Analysis | SniperIQ

Contineum Therapeutics (CTNM) is a US-listed Healthcare company in Biotechnology with a market capitalization of $552M, trading at

4.76 on the NASDAQ. This SniperIQ fundamentals page covers Contineum Therapeutics's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$552M
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Contineum Therapeutics's market cap?

Contineum Therapeutics (CTNM) has a market capitalization of approximately $552M, trading at

4.76 on the NASDAQ. Market cap moves with the live share price.

What is Contineum Therapeutics's P/E ratio?

Contineum Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Contineum Therapeutics?

Contineum Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Contineum Therapeutics pay a dividend?

Contineum Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Contineum Therapeutics financially healthy?

Contineum Therapeutics carries a debt-to-equity ratio of 0.03x and a current ratio of 38.00x, with a market beta of 0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Contineum Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Contineum Therapeutics (CTNM) the key facts are: market cap $552M, 52-week range 5.07-16.91. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Contineum Therapeutics's full fundamentals live

Get Contineum Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Candel Therapeutics (CADL) fundamentals · Prime Medicine (PRME) fundamentals · Kotra Industries (0002) fundamentals · Odyssey Therapeutics (ODTX) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons